46 participants
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-07-06
- Start Date:
- 2026-07-31
- Completion:
- 2028-06-30
Conditions
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- HER2-positive Gastric Cancer
Interventions
- DRUG
No Results Yet